• NeoGenomics, Inc. recently reported first-quarter 2026 results, with sales of US$186.67 million versus US$168.04 million a year earlier and a reduced net loss of US$17.11 million compared with US$25.92 million.
• In a separate development, Epic announced that NeoGenomics’ oncology testing portfolio is now accessible through Epic Aura, embedding the company’s cancer diagnostics directly into electronic health record workflows for oncologists and health systems across the United States.
• Next, we’ll examine how this combination of stronger quarterly revenue and deeper Epic integration could influence NeoGenomics’ longer-term investment narrative.

Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

NeoGenomics Investment Narrative Recap

To own NeoGenomics, you need to believe its focused oncology testing platform can eventually scale to profitable growth while managing intense competition and a still-unproven path to earnings. The latest quarter’s higher revenue and narrower loss help near term confidence, but the biggest risk remains the company’s high fixed cost base if test volumes or pharma demand soften. The Epic Aura integration strengthens the story around test access, but does not fully resolve profitability concerns.

The Epic Aura announcement is the most relevant development here, because it directly affects NeoGenomics’ ability to drive higher clinical test adoption within everyday oncology workflows. Easier ordering and result access inside Epic could support the company’s core catalyst of building volume across its PanTracer and MRD offerings, particularly as hospitals and practices seek integrated solutions. That said, the immediate financial impact of this integration is still uncertain and bears watching across future quarters.

Yet despite this progress, investors should be aware that NeoGenomics’ heavy fixed costs and ongoing losses mean that any slowdown in test volume growth could...

NeoGenomics' narrative projects $957.8 million revenue and $49.0 million earnings by 2029. This requires 9.6% yearly revenue growth and a $157.0 million earnings increase from -$108.0 million today.

Uncover how NeoGenomics' forecasts yield a $14.19 fair value, a 50% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts take a much more cautious view, assuming revenue of about US$966 million and earnings of only US$49 million by 2029, which contrasts sharply with the current enthusiasm around Epic-driven test adoption and highlights how differently you and other investors might interpret the same developments.

Explore 2 other fair value estimates on NeoGenomics - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your NeoGenomics research is our analysis highlighting 1 important warning sign that could impact your investment decision.
• Our free NeoGenomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NeoGenomics' overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.